Awaiting development: Guidance and quality standards
Showing 391 to 397 of 397
| Title | Type |
|---|---|
| Zanubrutinib with rituximab for untreated mantle cell lymphoma when a stem cell transplant is unsuitable [ID6641] | Technology appraisal guidance |
| Zasocitinib for treating moderate to severe plaque psoriasis [ID6700] | Technology appraisal guidance |
| Zavegepant for treating acute migraine [TSID11998] | Technology appraisal guidance |
| Zibotentan–dapagliflozin for treating chronic kidney disease with proteinuria [TSID12423] | Technology appraisal guidance |
| Zilurgisertib for preventing new heterotopic ossification lesions caused by fibrodysplasia ossificans progressiva in people 12 years and over [ID6637] | Technology appraisal guidance |
| Zimislecel for treating type 1 diabetes in people 12 years and over with impaired hypoglycaemic awareness and severe hypoglycaemia [ID6624] | Technology appraisal guidance |
| Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [TSID12040] | Technology appraisal guidance |